Table 5. Clinical characteristics based on PSA-based mass screening and clinical diagnosis.

Clinical characteristics	Whole cohort N>984		PSA screened N>259		PSA screened with later diagnosis N>99		Clinically diagnosed N>617		P value
Median age, year	71		72		74		70		P<0.0001
Clinical staging
T staging*									P<0.0001
T1	53	5.4%	18	6.9%	4	4.0%	31	5.0%
T2	382	38.8%	229	88.4%	76	76.8%	77	12.3%
T3	118	12.0%	6	2.3%	12	12.1%	100	16.0%
T4	181	18.4%	5	1.9%	7	7.1%	169	27.0%
Missing data	250	25.4%	1	0.4%	0	0.0%	249	39.8%
N staging*									N0 vs N1,2, P=0.0458
N0	517	52.5%	140	54.1%	19	19.2%	358	57.2%
N1,2	29	2.9%	2	0.8%	2	2.0%	25	4.0%
Nx	438	44.5%	117	45.2%	78	78.8%	243	38.8%
M staging*									M0 vs M1, P<0.0001
M0	500	50.8%	176	68.0%	32	32.3%	292	46.6%
M1	242	24.6%	77	29.7%	65	65.7%	100	16.0%
Mx	242	24.6%	6	2.3%	2	2.0%	234	37.4%
Median PSA(IQR), ng/mL	28	(0-1000)	20	(0.22-124)	68	(5.1-150)	38	(0-1000)	P<0.0001
Missing data	347	35.3%	0	0.0%	0	0.0%	347	56.2%
Gleason score									P<0.0001
<=6	206	20.9%	114	44.0%	22	22.2%	70	11.2%
7	175	17.8%	85	32.8%	28	28.3%	62	9.9%
8	115	11.7%	31	12.0%	30	30.3%	54	8.6%
9	111	11.3%	26	10.0%	18	18.2%	67	10.7%
10	24	2.4%	2	0.8%	1	1.0%	21	3.4%
Missing data	353	35.9%	1	0.4%	0	0.0%	352	56.2%
Management approach									P=0.0049
Curative	53	5.4%	24	9.3%	5	5.1%	24	3.8%
Non-curative	931	94.6%	235	90.7%	94	94.9%	602	96.2%
No. of all-cause death, no. (%)	261	26.5%	60	23.2%	40	40.4%	161	25.7%
No. of prostate cancer specific death, no. (%)	217	22.1%	30	11.6%	37	37.4%	150	24.0%
Median follow-up time, year	5	(0.08-23)	7	(1-16)	5	(1-11)	4	(0.08-23)	P<0.0001

IQR, interquartile range; *Percentages may not add up to 100 due to rounding.